The European Medicines Agency is this week deciding whether to fast track the planned EU marketing applications for three products, including maribavir, Takeda Pharmaceutical’s oral antiviral agent that the company claims could be a game-changer treatment for post-transplant cytomegalovirus (CMV) infection.
Maribavir is on track to being filed for approval in the EU and the US in the first half of...








